Tetracaine and Oxymetazoline
Medically reviewed by Drugs.com. Last updated on Jul 19, 2019.
(TET ra kane & oks i met AZ oh leen)
- Oxymetazoline and Tetracaine
- Tetracaine Hydrochloride and Oxymetazoline Hydrochloride
- Adrenergic Agonist Agent
- Imidazoline Derivative
- Local Anesthetic
Tetracaine: Local ester anesthetic that blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction.
Oxymetazoline: Imidazoline derivative with sympathomimetic activity that stimulates alpha-adrenergic receptors in the arterioles of the nasal mucosa to produce vasoconstriction.
Time to Peak
Pediatric patients 4 to 15 years of age: Oxymetazoline: ~10 to 30 minutes; Tetracaine metabolite (PBBA): ~20 to 30 minutes.
Adults: Oxymetazoline: 5 minutes; Tetracaine metabolite (PBBA): 20 minutes.
Pediatric patients 4 to 15 years of age: Oxymetazoline: ~1.6 to 4.3 hours; Tetracaine metabolite p-butylaminobenzoic acid (PBBA): ~1.6 to 2.8 hours.
Adults: Oxymetazoline: ~5.2 hours; Tetracaine metabolite (PBBA): ~2.6 hours.
Use: Labeled Indications
Anesthesia, dental: Regional anesthesia when performing a restorative procedure on teeth 4-13 and A-J in adults and children who weigh 40 kg or more.
Hypersensitivity to or intolerance of tetracaine, benzyl alcohol, other ester local anesthetics, p-aminobenzoic acid (PABA), oxymetazoline, or any component of the formulation.
Anesthesia, dental: Intranasal: 2 sprays administered 4 to 5 minutes apart in the nostril ipsilateral (same side) to the maxillary tooth on which the dental procedure will be performed. Initiate the dental procedure 10 minutes after the second spray. May administer 1 additional spray 10 minutes after the second initial spray if inadequate anesthesia.
Refer to adult dosing.
Anesthesia, dental: Children and Adolescents ≥3 years and ≥40 kg: Intranasal: 2 sprays administered 4 to 5 minutes apart in the nostril ipsilateral (same side) to the maxillary tooth on which the dental procedure will be performed. Initiate the dental procedure 10 minutes after the second spray.
For intranasal use only. Administer ipsilateral (same side) to the maxillary tooth on which the dental procedure will be performed. Wait 10 minutes following administration to perform a test drill to confirm that the tooth involved is anesthetized. Avoid use with other intranasal products, including other oxymetazoline-containing nasal sprays. Discontinue oxymetazoline-containing products 24 hours prior to administration of tetracaine/oxymetazoline.
Store between 2°C and 8°C (36°F and 46°F); excursions permitted between 0°C and 15°C (32°F and 59°F). Discard any unused solution. Do not use if kept at room temperature for >5 days.
Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation. Monitor therapy
AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics. Monitor therapy
Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics. Exceptions: Cannabidiol. Monitor therapy
Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Consider therapy modification
Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Monitor therapy
Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. Monitor therapy
Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists. Exceptions: Ergoloid Mesylates; Nicergoline. Avoid combination
Esketamine: Decongestants (Nasally Administered) may diminish the therapeutic effect of Esketamine. Management: Patients who require a nasal decongestant on an esketamine dosing day should administer the nasal decongestant at least 1 hour before esketamine. Consider therapy modification
FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed. Monitor therapy
Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics. Monitor therapy
Iobenguane Radiopharmaceutical Products: Alpha1-Agonists may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose. Avoid combination
Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available. Consider therapy modification
Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Monitor therapy
Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Monitor therapy
Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors. Refer to linezolid specific monographs for details. Exceptions: Linezolid; Tedizolid. Avoid combination
Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia. Avoid lidocaine/prilocaine. Monitor therapy
Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia. Avoid lidocaine/prilocaine in infants receiving such agents. Monitor therapy
Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Monitor therapy
Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Monitor therapy
Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Monitor therapy
Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Monitor therapy
Tricyclic Antidepressants: May enhance the therapeutic effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the therapeutic effect of Alpha1-Agonists. Monitor therapy
Also see individual agents.
Ophthalmic: Increased lacrimation (13%)
Respiratory: Rhinorrhea (52%), nasal congestion (32%), nasal discomfort (26%), oropharyngeal pain (14%)
1% to 10%:
Cardiovascular: Increased systolic blood pressure (5%), bradycardia (3%), hypertension (3%), increased diastolic blood pressure (3%)
Central nervous system: Headache (10%), hypoesthesia (intranasal: 10%; pharyngeal: 10%), nasal cavity pain (6%), dizziness (3%), abnormal sensory symptoms (2%)
Gastrointestinal: Dysgeusia (8%), oral discomfort (2%), dysphagia (1%)
Respiratory: Throat irritation (9%), sneezing (4%), nasal mucosa ulcer (3%), sinus headache (3%), dry nose (2%), epistaxis (2%)
Concerns related to adverse effects:
• Anaphylactic Reactions: Allergic or anaphylactoid reactions, including urticaria, angioedema, bronchospasm, and shock may occur.
• Dysphagia: Has been reported; monitor patients for dysphagia.
• Epistaxis: Has been reported. Avoid use in patients with a history of frequent nose bleeds (≥5 per month); if administration cannot be avoided, monitor patients with frequent nose bleeds carefully.
• Hypertension: May occur; monitor patients for increased blood pressure. Use is not recommended in patients with uncontrolled hypertension.
• Methemoglobinemia: Has been reported with local anesthetics; clinically significant methemoglobinemia requires immediate treatment along with discontinuation of the anesthetic and other oxidizing agents. Onset may be immediate or delayed (hours) after anesthetic exposure. Patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, exposure to oxidizing agents or their metabolites, or infants <6 months of age are more susceptible and should be closely monitored for signs and symptoms of methemoglobinemia (eg, cyanosis, headache, rapid pulse, shortness of breath, lightheadedness, fatigue).
• Hepatic impairment: Patients with severe hepatic impairment may be at greater risk of developing toxic plasma concentrations of tetracaine due to inability to metabolize local anesthetics. Monitor patients with hepatic disease for signs of local anesthetic toxicity.
• Pseudocholinesterase deficiency: Patients with pseudocholinesterase deficiency may be at a greater risk of developing toxic plasma concentrations of tetracaine due to inability to metabolize local anesthetics. Monitor for signs of local anesthetic toxicity.
• Thyroid disease: Use is not recommended in patients with inadequately controlled active thyroid disease.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
Dosage form specific issues:
• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP 1997; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer′s labeling.
• Appropriate use: Avoid use with other intranasal products, including other oxymetazoline-containing nasal sprays. Discontinue oxymetazoline-containing products 24 hours prior to administration of tetracaine/oxymetazoline.
Blood pressure; monitor for dysphagia, epistaxis, and signs of local anesthetic toxicity, especially in patients with hepatic impairment or pseudocholinesterase deficiency.
Adverse events have been observed in some animal reproduction studies using this combination subcutaneously. See individual monographs.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience nosebleed, rhinorrhea, rhinitis, pharyngitis, throat pain, watery eyes, headache, or change in taste. Have patient report immediately to prescriber severe headache, dizziness, passing out, vision changes, difficulty swallowing, or signs of methemoglobinemia (blue or gray color of the lips, nails, or skin; abnormal heartbeat; seizures; severe dizziness or passing out; severe headache; fatigue; loss of strength and energy; or shortness of breath) (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about oxymetazoline / tetracaine nasal
Other brands: Kovanaze